4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 95 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,005,909 | -67.3% | 95,565 | -50.3% | 0.01% | -69.6% |
| Q1 2024 | $6,129,259 | +139.0% | 192,381 | +52.0% | 0.02% | +109.1% |
| Q4 2023 | $2,564,693 | +24.9% | 126,589 | -21.5% | 0.01% | -8.3% |
| Q3 2023 | $2,053,171 | -42.4% | 161,286 | -18.2% | 0.01% | -40.0% |
| Q2 2023 | $3,562,591 | +53.8% | 197,155 | +46.3% | 0.02% | +25.0% |
| Q1 2023 | $2,317,006 | +117.6% | 134,788 | +181.2% | 0.02% | +77.8% |
| Q4 2022 | $1,064,592 | -1.9% | 47,933 | -33.2% | 0.01% | +50.0% |
| Q1 2022 | $1,085,000 | -34.7% | 71,774 | -5.2% | 0.01% | -33.3% |
| Q4 2021 | $1,661,000 | – | 75,713 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |